1Department of Pathology, Albany Medical Center, Albany, NY, USA
2Division of Anatomic Pathology, Department of Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA
3Division of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
4Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
5Albany Medical College, Albany, NY, USA
6GE Global Research, Niskayuna, NY, USA
© 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
The study was approved by the Institutional Review Board (IRB) at Albany Medical College (protocol #5718 06/18/2020) and Penn State Medical Center. All procedures performed in the current study were approved by IRB in accordance with the 1964 Helsinki declaration and its later amendments. Formal written informed consent was not required with a waiver by the appropriate IRB.
Availability of Data and Material
All data generated or analyzed during the study are included in this published article (and its supplementary information files).
Code Availability
Not applicable.
Author contributions
Conceptualization: Hwajeong Lee. Data curation: MEA, RB, LG, DK, KH, Hua Li, SA. Formal analysis: MEA, SA, Hwajeong Lee. Investigation: MEA, Hwajeong Lee. Methodology: MEA, SA, Hwajeong Lee. Project administration: Hwajeong Lee. Supervision: Hwajeong Lee. Visualization: MEA, SA. Writing—original draft: MEA, Hwajeong Lee. Writing—review & editing: RB, LG, DK, MWM, KH, Hua Li, SA. Approval of final manuscript: all authors.
Conflicts of Interest
The authors declare that they have no potential conflicts of interest. SA contributed to this article in his personal capacity. The views expressed are his own and do not necessarily represent the views of General Electric.
Funding Statement
No funding to declare.
Parameter | All CD | Stricturing CD | Inflammatory CD | Controls |
---|---|---|---|---|
No. of cases | 44 | 31 | 13 | 20 |
No. of images | 1,791 | 1,321 | 470 | 486 |
Proximal margin | ||||
Proximal-PC-calr, mean (%) | 1.352 | 1.415 | 1.202 | 1.113 |
Proximal-PC-CD34, mean (%) | 17.718 | 17.245 | 19.284 | 17.800 |
Proximal/mid-CD34 | 1.479 | 1.481 | 1.439 | - |
Proximal-PC-calp, mean (%) | 0.362 | 0.397 | 0.218 | 0.338 |
Distal margin | ||||
Distal-PC-calr, mean (%) | 2.407 | 2.480 | 2.234 | 1.434a |
Distal-PC-CD34, mean (%) | 18.972 | 19.287 | 16.297 | 15.156 |
Proximal/distal-PC-calr | 0.588 | 0.594 | 0.574 | 1.062 |
Distal-PC-calp, mean (%) | 0.396 | 0.436 | 0.274 | 1.120 |
Mid-section | ||||
Mid-PC-CD34, mean (%) | 13.473 | 13.087 | 14.394 | - |
Mid-PC-CD34-hotspot, mean (%) | 17.330 | 16.795 | 18.606 | - |
Mid-PC-calp, mean (%) | 10.975 | 9.929 | 13.468 | - |
Mid-PC-calp-hotspot, mean (%) | 16.524 | 15.139 | 19.826 | - |
The numbers in round bracket indicate r in stricturing Crohn’s disease; The numbers in square bracket indicate r in inflammatory Crohn’s disease; all p < .05.
p, proximal; PC, pixel count; calr, calretinin; p/d, proximal/distal; p/m, proximal/mid; m, mid; calp, calprotectin; SM, submucosal thickness; MP, muscularis propria thickness.
Parameter | All CD | Stricturing CD | Inflammatory CD | Controls |
---|---|---|---|---|
No. of cases | 44 | 31 | 13 | 20 |
No. of images | 1,791 | 1,321 | 470 | 486 |
Proximal margin | ||||
Proximal-PC-calr, mean (%) | 1.352 | 1.415 | 1.202 | 1.113 |
Proximal-PC-CD34, mean (%) | 17.718 | 17.245 | 19.284 | 17.800 |
Proximal/mid-CD34 | 1.479 | 1.481 | 1.439 | - |
Proximal-PC-calp, mean (%) | 0.362 | 0.397 | 0.218 | 0.338 |
Distal margin | ||||
Distal-PC-calr, mean (%) | 2.407 | 2.480 | 2.234 | 1.434 |
Distal-PC-CD34, mean (%) | 18.972 | 19.287 | 16.297 | 15.156 |
Proximal/distal-PC-calr | 0.588 | 0.594 | 0.574 | 1.062 |
Distal-PC-calp, mean (%) | 0.396 | 0.436 | 0.274 | 1.120 |
Mid-section | ||||
Mid-PC-CD34, mean (%) | 13.473 | 13.087 | 14.394 | - |
Mid-PC-CD34-hotspot, mean (%) | 17.330 | 16.795 | 18.606 | - |
Mid-PC-calp, mean (%) | 10.975 | 9.929 | 13.468 | - |
Mid-PC-calp-hotspot, mean (%) | 16.524 | 15.139 | 19.826 | - |
p-PC-calr | p/d-PC-calr | p-PC-CD34 | p/m-PC-CD34 | m-PC-CD34 | m-PC-CD34-hotspot | m-PC-calphotspot | d-PC-CD34 | ||
---|---|---|---|---|---|---|---|---|---|
Proximal margin | |||||||||
SM | - | - | - | 0.41 (0.46) | –0.46 (–0.45) | –0.42 (–0.42) | - | - | |
SM/MP | 0.39 (0.40) | 0.37 (0.42) | - | 0.31 (0.42) | –0.32 | –0.32 | - | - | |
SM/(SM + MP) | 0.34 | 0.33 (0.37) | - | (0.40) | –0.31 | –0.31 | - | - | |
MP | - | - | (–0.37) [0.60] | [0.62] | - | - | - | - | |
MP/(SM + MP) | –0.34 | - | - | - | 0.50 | 0.48 | - | - | |
Mid-section | |||||||||
SM | - | - | - | - | - | - | - | (0.39) | |
SM/MP | - | - | - | - | - | - | (0.39) | - | |
SM/(SM + MP) | –0.39 [–0.56] | –0.35 (–0.38) | - | - | - | - | - | - | |
MP | [0.82] | - | - | - | - | - | - | - | |
MP/(SM + MP) | 0.39 [0.56] | 0.35 (0.40) | - | - | - | - | - | - | |
Distal margin | |||||||||
SM | - | - | - | - | - | –0.32 | - | [0.57] | |
SM/MP | - | - | - | - | - | - | - | [0.56] | |
SM/(SM + MP) | - | - | - | - | - | - | - | [0.64] | |
MP | 0.31 | - | - | - | - | - | - | - | |
MP/(SM + MP) | - | - | - | - | - | - | - | [–0.64] |
CD, Crohn’s disease; PC, pixel count; calr, calretinin; calp, calprotectin. p < .05 by student’s t-test.
The numbers in round bracket indicate r in stricturing Crohn’s disease; The numbers in square bracket indicate r in inflammatory Crohn’s disease; all p < .05. p, proximal; PC, pixel count; calr, calretinin; p/d, proximal/distal; p/m, proximal/mid; m, mid; calp, calprotectin; SM, submucosal thickness; MP, muscularis propria thickness.